EA201071300A1 - Антитела к cxcr4 - Google Patents

Антитела к cxcr4

Info

Publication number
EA201071300A1
EA201071300A1 EA201071300A EA201071300A EA201071300A1 EA 201071300 A1 EA201071300 A1 EA 201071300A1 EA 201071300 A EA201071300 A EA 201071300A EA 201071300 A EA201071300 A EA 201071300A EA 201071300 A1 EA201071300 A1 EA 201071300A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
cxcr4
present
metastasis
angiogenesis
Prior art date
Application number
EA201071300A
Other languages
English (en)
Inventor
Синди Такеучи Дикерсон
Дэвид Мэттью Маркис
Виктор Обунгу
Шэн-бинь Пэн
Питер Эдвард Вайлланкур
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201071300A1 publication Critical patent/EA201071300A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение обеспечивает антитела, которые связывают CXCR4 человека и известны в данной области техники как обладающие высоким сродством и сильными нейтрализующими свойствами. Антитела согласно настоящему изобретению применяют для лечения опухолеобразования, включая рост опухоли, инвазию, ангиогенез или метастазирование.
EA201071300A 2008-05-14 2009-05-07 Антитела к cxcr4 EA201071300A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5319208P 2008-05-14 2008-05-14
PCT/US2009/043063 WO2009140124A1 (en) 2008-05-14 2009-05-07 Anti-cxcr4 antibodies

Publications (1)

Publication Number Publication Date
EA201071300A1 true EA201071300A1 (ru) 2011-06-30

Family

ID=40852496

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071300A EA201071300A1 (ru) 2008-05-14 2009-05-07 Антитела к cxcr4

Country Status (11)

Country Link
EP (1) EP2297206A1 (ru)
JP (1) JP2011520885A (ru)
KR (1) KR20100133012A (ru)
CN (1) CN102027015A (ru)
AU (1) AU2009246683A1 (ru)
CA (1) CA2724409A1 (ru)
EA (1) EA201071300A1 (ru)
IL (1) IL208869A0 (ru)
MX (1) MX2010012435A (ru)
WO (1) WO2009140124A1 (ru)
ZA (1) ZA201007955B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172485A1 (en) * 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
EP2396023A2 (en) 2009-02-11 2011-12-21 Yeda Research and Development Co. Ltd. Short beta-defensin-derived peptides
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
GB201002238D0 (en) 2010-02-10 2010-03-31 Affitech As Antibodies
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
AU2011322508A1 (en) * 2010-10-27 2013-05-02 Pierre Fabre Medicament Antibodies for the treatment of HIV
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US20140314784A1 (en) * 2011-07-20 2014-10-23 Medlmmune Limited Anti-cxcr4 antibodies and methods of use
AR087364A1 (es) 2011-07-29 2014-03-19 Pf Medicament Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
DK2776032T3 (en) * 2011-11-09 2019-02-04 Bristol Myers Squibb Co TREATMENT OF HEMATOLOGICAL MALIGNITIES WITH ANTI-CXCR4 ANTIBODY
JO3580B1 (ar) * 2013-03-15 2020-07-05 Lilly Co Eli أجسام مضادة لكيموكين elr+ cxc شامل
CA2989144A1 (en) 2015-06-12 2016-12-15 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
EP3765519B1 (en) 2018-03-13 2024-01-17 Fundación para la Investigación Biomédica del Hospital Universitario la Paz Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy
US20210024873A1 (en) 2018-03-27 2021-01-28 Bristol-Myers Squibb Company Real-time monitoring of protein concentration using ultraviolet signal
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
WO2020237221A1 (en) 2019-05-23 2020-11-26 Bristol-Myers Squibb Company Methods of monitoring cell culture media
KR20230080460A (ko) 2020-10-05 2023-06-07 브리스톨-마이어스 스큅 컴퍼니 단백질을 농축시키는 방법
CN112661845B (zh) * 2020-12-25 2022-06-21 暨南大学 与cxcr4结合的亲和力成熟结合蛋白及其应用
CN112521500B (zh) * 2020-12-25 2022-06-24 暨南大学 与cxcr4结合的亲和力成熟结合蛋白及应用
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19801265C1 (de) * 1998-01-15 1999-08-12 Deutsches Krebsforsch Inhibierung von CD95-unabhängiger Apoptose bei AIDS
US20050002939A1 (en) * 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
EP1871807B1 (en) * 2005-02-18 2012-11-28 Dana-Farber Cancer Institute, Inc. Antibodies against cxcr4 and methods of use thereof
PL2066351T3 (pl) * 2006-10-02 2016-02-29 Squibb & Sons Llc Przeciwciała ludzkie wiążące CXCR4 i ich wykorzystanie
FR2915102B1 (fr) * 2007-04-23 2014-05-16 Pf Medicament Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer

Also Published As

Publication number Publication date
AU2009246683A1 (en) 2009-11-19
IL208869A0 (en) 2011-01-31
MX2010012435A (es) 2011-05-03
KR20100133012A (ko) 2010-12-20
CN102027015A (zh) 2011-04-20
CA2724409A1 (en) 2009-11-19
EP2297206A1 (en) 2011-03-23
WO2009140124A1 (en) 2009-11-19
JP2011520885A (ja) 2011-07-21
ZA201007955B (en) 2012-04-25

Similar Documents

Publication Publication Date Title
EA201071300A1 (ru) Антитела к cxcr4
EA200970874A1 (ru) Антитела против склеростина
EA201590085A1 (ru) Антитела анти-egfr и их применение
PH12014502419A1 (en) Specific binding proteins and uses thereof
EA201490717A1 (ru) АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ
EA201390472A1 (ru) Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
EA201201000A1 (ru) Способы лечения колоректального рака
EA201170155A1 (ru) Специфические антагонисты рецептора fgf-r4
MY177062A (en) Cd37-binding molecules and immunoconjugates thereof
NZ599737A (en) Il-17a antagonists
UA112416C2 (uk) Антитіло до fap і способи його застосування
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
JO3097B1 (ar) الأجسام المضادة c-Met
MX348637B (es) Anticuerpos y composiciones anti-her3.
EA201001639A1 (ru) Композиции и способы их получения и применения
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
EA202090031A2 (ru) Человеческие антитела против gfr3 и способы их применения
EA201171237A1 (ru) Антитела к dkk-1
EA201290360A1 (ru) Гуманизированные антитела против il-22ra человека
MX2012001306A (es) Inhibicion de matastasis de tumor.
MX2020011759A (es) Construcciones de variantes de sirp-alfa y sus usos.
EA201891594A1 (ru) Антитела к il-17c
MX2013011596A (es) Anticuerpos que se unen a tgf-alfa y epiregulina.
EA202092640A1 (ru) Способы и композиции для лечения хронической крапивницы
EA201992840A3 (ru) Конструкции варианта sirp-альфа и их применение